Refractory Status Epilepticus Epidemiology Forecast to 2030

Refractory Status Epilepticus Epidemiology Forecast to 2030

“Delveinsight Business Research”
DelveInsight’s ‘Refractory Status Epilepticus Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Refractory Status Epilepticus epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Status Epilepticus (SE) is an important neurological emergency defined as seizures lasting for 5 minutes or more or recurrent seizures without recovery of consciousness to baseline between the attacks. The causes of SE vary; including stroke, infections, trauma and metabolic disorders. In children, fevers also are a causal factor. 

Refractory Status Epilepticus (RSE) is defined as SE persisting despite sufficient dose of benzodiazepines and at least one antiepileptic drug (AED), irrespective of time. RSE is associated with acute, severe, and potentially fatal underlying etiologies such as encephalitis, massive stroke, or rapidly progressive primary brain tumors, and may be accompanied by severe impairment of consciousness.

In general, RSE occurs in patients with new-onset seizures rather than in patients with chronic epilepsy. The etiology of RSE in developing countries is dominated by central nervous system (CNS) infections and head injury compared to stroke and drug withdrawal in the developed countries. 

More prolonged seizures carry higher risk of mortality; therefore the treatment is categorized into pre hospital treatment and In hospital treatment. There is no significant difference in the occurrence of RSE in males and females

The DelveInsight Refractory Status Epilepticus epidemiology report gives a thorough understanding of the Refractory Status Epilepticus by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. 

It also provides treatment algorithms and treatment guidelines for Refractory Status Epilepticus in the US, Europe, and Japan. The report covers the detailed information of the Refractory Status Epilepticus epidemiology scenario in seven major countries (US, EU5, and Japan).

 

Key Highlights Of The Report

Mortality from SE varies from 3–50% in different studies. In elderly patients, refractory status epilepticus (RSE) may lead to death in over 76% cases.

Refractory Status Epilepticus occurs in 29 – 43% of Status Epilepticus cases (Novy et al.) 

A recent article by Leitinger et al. reporting SE frequency of 36.1/100,000.

According to Stuntz M(Deerfield Institute, New York, NY, USA) the prevalence of SE to be 18.4 cases per 10,000 population in the 5EU, resulting in 590,264 cases in 2015 and increasing to 603,951 in 2024.

 Refractory Status Epilepticus Epidemiology

Request for Sample Pages: 

https://www.delveinsight.com/sample-request/refractory-status-epilepticus-rse-epidemiology-forecast

 

Refractory Status Epilepticus Epidemiology

Delveinsight’s Refractory Status Epilepticus epidemiology division provides insights about historical and current patient pool and forecasted trends for every seven major countries. 

The Refractory Status Epilepticus epidemiology data are studied through all possible divisions to give a better understanding of the Disease scenario in 7MM. 

The Refractory Status Epilepticus epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. 

It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

 

Scope of the Report

  • The report provides insight into the historical and forecasted patient pool of Refractory Status Epilepticus in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.

  • The report assesses the disease risk and burden and highlights the unmet needs of Refractory Status Epilepticus.

  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.

  • The Refractory Status Epilepticus report provides a detailed overview explaining Refractory Status Epilepticus causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns.

  • The Refractory Status Epilepticus Epidemiology Report and Model provide an overview of the risk factors and global trends of Refractory Status Epilepticus in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan).

  • The report provides the segmentation of the Refractory Status Epilepticus epidemiology. 

 

Key Questions Covered In The Refractory Status Epilepticus Report Include:

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Refractory Status Epilepticus?

  • What are the key findings pertaining to the Refractory Status Epilepticus epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?

  • What would be the total number of patients of Refractory Status Epilepticus across the 7MM during the forecast period (2017-2030)?

  •  Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?

  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?

  • What is the disease risk, burden and unmet needs of the Refractory Status Epilepticus?

  • What are the currently available treatments of Refractory Status Epilepticus?

 

Key Benefit of Refractory Status Epilepticus Epidemiology Report 

  • The Refractory Status Epilepticus Epidemiology report will allow the user to –

  • Develop business strategies by understanding the trends shaping and driving the global Refractory Status Epilepticus market

  • Quantify patient populations in the global Refractory Status Epilepticus market to improve product design, pricing, and launch plans

  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Refractory Status Epilepticus therapeutics in each of the markets covered

  • Understand the magnitude of Refractory Status Epilepticus population by its epidemiology

  • The Refractory Status Epilepticus Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

 

Table of Contents

  1. Key Insights 

  2. Executive Summary of Refractory Status Epilepticus

  3. Refractory Status Epilepticus Disease Background and Overview

  • Refractory Status Epilepticus Sign and Symptoms

  • Refractory Status Epilepticus Pathophysiology

  • Refractory Status Epilepticus Risk Factors

  • Refractory Status Epilepticus Diagnosis

  1. Refractory Status Epilepticus Patient Journey

  2. Refractory Status Epilepticus Epidemiology and Patient Population

  3. Refractory Status Epilepticus Treatment Algorithm, Current Treatment, and Medical Practices

  4. KOL Views on Refractory Status Epilepticus 

  5. Refractory Status Epilepticus Unmet Needs

  6. Appendix

  7. DelveInsight Capabilities

  8. Disclaimer

*The table of contents is not exhaustive; will be provided in the final report

About  DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

 

Related Reports-

Refractory Status Epilepticus (RSE) Market Insight, Epidemiology and Market Forecast 2030
DelveInsight’ s Refractory Status Epilepticus (RSE) Market Insights, Epidemiology and Market Forecast 2030 report provides the detailed overview of the disease and in depth understanding of historical and forecasted epidemiology.

 

 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/